Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapy with cells from human placenta and hematopoietic cells

A technology of hematopoietic cells and human placenta, applied in animal cells, extracellular fluid diseases, vertebrate cells, etc., can solve problems such as delay in transplantation time, recipient death, and cell number limitation

Pending Publication Date: 2016-07-20
ANTHROGENESIS LLC
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, current UCB cell transplantation therapies have drawbacks, including limitations on the number of cells that can be transplanted
Safety and efficacy are compromised when transplantation of large numbers of UCB cells is required, e.g., greater than one unit
Additionally, there is a risk of graft failure and GVHD, especially when the HLA match is incomplete
Another disadvantage of HSCT using UCB relative to bone marrow or peripheral blood is the delay in transplantation time, which often results in the death of the recipient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] 5.1 Example 1: Unrelated Cord Blood and Perfusion from Human Placenta in Patients with Metabolic Disorders Transplantation of Mismatched Monocytes

[0099] This example describes the successful administration of unrelated umbilical cord blood (UCB) and mismatched monocytes from human placental perfusate to patients with metabolic disorders.

[0100] The patient was an 11-year-old male with adrenoleukodystrophy (ALD), an aggressive mutation. Patients received reduced toxicity conditioning on approximately Day -8. On day 0, patients received transplantation by perfusion of a single unit of unrelated UCB and unrelated, mismatched monocytes (either with the patient recipient or with UCB) from human placental perfusate. Specifically, patients received a single UCB donor product (6 / 6 HLA-matched; approximately 3.9×10 7 Total cells / kg; about 2.8×10 5 CD34+ cells / kg) and about 0.6×10 from the perfusate 7 cells / kg (about 0.3×10 5 The combined total nucleated cell dose (...

Embodiment 2

[0103] 5.2 Example 2: Unrelated Cord Blood and Human Placenta from a Patient with a Malignant Disease (#1) Transplantation of Perfusate-Mismatched Monocytes

[0104] This example describes the safe, successful administration of unrelated umbilical cord blood (UCB) and mismatched, unrelated monocytes from human placental perfusate to patients with the malignancy acute lymphoblastic leukemia (ALL) .

[0105] The patient was a 22-year-old female patient with ALL. Patients underwent chemotherapy as described above and received detoxification treatment at approximately day -8 prior to the administration of unrelated UCB and mismatched, unrelated monocytes from human placental perfusate. The patient showed complete myelosuppression upon administration of unrelated UCB and mismatched, unrelated monocytes from human placental perfusate. On day 0, the patient received two unrelated cord UCB units (both units were 5 / 6 HLA matched; one unit contained approximately 3 × 10 7 cells / k...

Embodiment 3

[0108] 5.3 Example 3: Unrelated Cord Blood and Human Placenta from a Patient with a Malignant Disease (#2) Transplantation of Perfusate-Mismatched Monocytes

[0109] This example is designed to evaluate the transfer of mismatched, unrelated umbilical cord blood (UCB) and mismatched, unrelated monocytes from human placental perfusate to patients with the malignant disease acute lymphoblastic leukemia (ALL) application.

[0110] The patient is a 17 year old female with ALL in CR1 (induction failure). On approximately day -8, patients received myeloablative conditioning or detoxification treatments. On day 0, the patient received two unrelated cord UCB units (both units were 4 / 6 HLA matched; one unit contained approximately 2.7 × 10 7 cells / kg (about 3.6×10 5 CD34+ cells / kg), the other contains about 2.7×10 7 cells / kg (about 2.5×10 5 CD34+ cells / kg) and mismatched, unrelated monocytes (approximately 0.3×10 7 cells / kg; about 0.2×10 5 CD34+ cells / kg of TNC). Transplanta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

Description

[0001] This application claims the rights and interests of U.S. Provisional Patent Application No. 61 / 890,057 filed on October 11, 2013 and U.S. Provisional Patent Application No. 61 / 886,648 filed on October 3, 2013. The disclosures of the above patent applications are based on their The entire contents of are incorporated herein by reference. 1. Technical field [0002] Provided herein are methods of treatment comprising administering to a subject (e.g., a human subject) monocytes and hematopoietic cells from human placental perfusate and compositions comprising them, and their establishment of chimerism, implantation into tissues ( For example, use of blood), reducing the severity or duration of graft-versus-host disease, and treating or ameliorating the symptoms of metabolic disorders and hematological disorders such as hematological malignancies. 2. Background of the invention [0003] In allogeneic hematopoietic stem cell transplantation (HSCT), stem cells from one indi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/51A61K35/50A61K35/28A61P35/00A61P7/04A61P25/28A61P35/02A61P37/04A61P7/06
CPCA61K35/12A61K35/51A61K2035/124A61K35/50A61P25/28A61P3/00A61P35/00A61P35/02A61P37/04A61P37/06A61P43/00A61P7/00A61P7/04A61P7/06A61K2300/00A61K35/15A61K35/28A61K2035/122C12N5/0647
Inventor 乔迪·P·格尼张小葵斯泰西·赫布罗伯特·J·哈黎里
Owner ANTHROGENESIS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com